The Successful Retreatment with Glecaprevir and Pibrentasvir of Genotype 1 or 2 HCV-infected Hemodialysis Patients who Failed to Respond to NS5A and Protease Inhibitor Treatment

Clinical trials and real-world data have proven that hepatitis C virus (HCV) in most infected patients can be eradicated by direct-acting antivirals (DAAs). However, the proper retreatment regimen for hemodialysis patients with HCV infection who have previously failed to respond to DAAs has not been...

Full description

Saved in:
Bibliographic Details
Published in:Internal Medicine 2019/04/01, Vol.58(7), pp.943-947
Main Authors: Suda, Goki, Nakai, Masato, Sho, Takuya, Kimura, Megumi, Shimazaki, Tomoe, Maehara, Osamu, Shigesawa, Taku, Suzuki, Kazuharu, Nakamura, Akihisa, Ohara, Masatsugu, Umemura, Machiko, Kawagishi, Naoki, Baba, Masaru, Natsuizaka, Mitsuteru, Morikawa, Kenichi, Ogawa, Koji, Sakamoto, Naoya, for the NORTE Study Group
Format: Article
Language:English
Subjects:
Aged
Anti-Retroviral Agents - therapeutic use
Antiretroviral drugs
Antiviral agents
Antiviral Agents - therapeutic use
Benzimidazoles - therapeutic use
Case Report
Clinical trials
Drug Therapy, Combination
Female
Genotype
Genotypes
glecaprevir
HCV
Hemodialysis
Hepacivirus - drug effects
Hepacivirus - genetics
Hepatitis
Hepatitis C
Hepatitis C, Chronic - drug therapy
Hepatitis C, Chronic - virology
Humans
Imidazoles - therapeutic use
Infections
Internal medicine
Isoquinolines - therapeutic use
Middle Aged
Patients
pibrentasvir
Protease
Protease inhibitors
Protease Inhibitors - therapeutic use
Proteinase inhibitors
Quinoxalines - therapeutic use
Renal Dialysis
retreatment
Retreatment - methods
Sulfonamides - therapeutic use
Treatment Failure
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Clinical trials and real-world data have proven that hepatitis C virus (HCV) in most infected patients can be eradicated by direct-acting antivirals (DAAs). However, the proper retreatment regimen for hemodialysis patients with HCV infection who have previously failed to respond to DAAs has not been clarified. We herein report, for the first time, the successful retreatment with glecaprevir and pibrentasvir, of three hemodialysis patients with genotype 1 or 2 HCV infection, who had previously failed to respond to combination therapy with an HCV-NA5A inhibitor (daclatasvir) and an HCV protease inhibitor (asunaprevir).
ISSN:0918-2918
1349-7235
DOI:10.2169/internalmedicine.2077-18